Contraceptive Technology Update
RSSArticles
-
Pharmacist-Prescribed Contraception Effective in Oregon
Study findings indicate that in the first two years after the Oregon law went into effect in 2016, pharmacist-prescribed contraception prevented more than 50 unintended pregnancies and saved an estimated $1.6 million in associated taxpayer costs.
-
Help Us Help You
Take our annual reader survey and tell us how we can better serve you.
-
New Progestin-Only Pill Receives FDA Approval
Women who are seeking an estrogen-free form of contraception now have a new option: Slynd, a drospirenone progestin-only pill. The pill is scheduled for release in fall 2019.
-
Counsel Teens on Dual Use of Condoms with LARC Methods
While more adolescents are choosing long-acting reversible contraceptive methods, they may not be implementing dual use of condoms to protect themselves from sexually transmitted infections.
-
Annual User Survey
-
Drug Combination Considered for Treatment-Resistant Gonorrhea
Newly released research indicates that a certain combination of drugs, gentamicin and azithromycin, may work as well as ceftriaxone alone for cases of drug-resistant gonorrhea.
-
Time to Close Gaps in HIV Testing, Treatment
About 80% of new HIV transmissions can be linked to people whose infection is undiagnosed or is not currently treated, according to findings from a just-published analysis.
-
Legislators, Listen Up, Learn, and Perhaps Beware
Combined oral contraceptives have been shown to provide health benefits beyond birth control.
-
Science Focuses on the Use of Metronidazole for Endometriosis
Researchers are exploring the use of metronidazole for the treatment of endometriosis, which affects up to 10% of U.S. women between the ages of 25 and 40. The current treatment options include hormone therapy and surgery, but these approaches involve significant side effects and recurrence of the condition after treatment.
-
Overcome Barriers to HPV Vaccination
A new analysis of a national survey underscores the importance of continued efforts to strengthen practitioner adoption of evidence-based approaches to recommending the HPV vaccine.